

# Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020

Greg Davis,<sup>1#</sup> Allen J. York,<sup>1#</sup> Willis Clark Bacon,<sup>1#</sup> Suh-Chin, Lin,<sup>1</sup> Monica Malone McNeal,<sup>1</sup> Alexander E. Yarawsky,<sup>1</sup> Joseph J. Maciag,<sup>1</sup> Jeanette L. C. Miller,<sup>1</sup> Kathryn C. S. Locker,<sup>1</sup> Michelle Bailey,<sup>2</sup> Rebecca Stone,<sup>2</sup> Michael Hall,<sup>2</sup> Judith Gonzalez,<sup>2</sup> Alyssa Sproles,<sup>1</sup> E. Steve Woodle,<sup>3</sup> Kristen Safier,<sup>1</sup> Kristine A. Justus,<sup>1</sup> Paul Spearman,<sup>1</sup> Russell E. Ware,<sup>1</sup> Jose A. Cancelas,<sup>2</sup> Michael B. Jordan,<sup>1</sup> Andrew B. Herr,<sup>1</sup> David A. Hildeman,<sup>1</sup> Jeffery D. Molkentin<sup>1,4\*</sup>

<sup>1</sup>Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.

<sup>2</sup>Hoxworth Blood Center, University of Cincinnati College of Medicine, Cincinnati OH, 45267, USA

<sup>3</sup>Department of Surgery, University of Cincinnati College of Medicine, Cincinnati OH, 45267, USA

<sup>4</sup>Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.

## \*Correspondence:

Jeffery D. Molkentin  
Howard Hughes Medical Institute,  
Cincinnati Children's Hospital Medical Center  
240 Albert Sabin Way  
Cincinnati, OH 45229.  
E-mail: jeff.molkentin@cchmc.org

#These authors contributed equally to this work

## Abstract

The world is currently in a pandemic of COVID-19 (Coronavirus disease-2019) caused by a novel positive-sense, single-stranded RNA  $\beta$ -coronavirus referred to as SARS-CoV-2. Fortunately, most infected individuals recover and are then resistant to re-infection for a period, indicating that a vaccination approach can be successful. Elucidation of rates of past SARS-CoV-2 infection within select regions across the United States of America (USA) will help direct vaccination efforts and together will inform our approach towards achieving herd immunity. Here we investigated rates of SARS-CoV-2 infection in the greater Cincinnati, Ohio, USA metropolitan area from August to December 2020, just prior to initiation of the national vaccination program. Examination of 9,550 adult blood donor volunteers for serum IgG antibody positivity against the SARS-CoV-2 Spike protein showed an overall prevalence of 8.40%, measured as 7.56% in the first 58 days of this time frame, versus a significant increase to 9.24% in the last 58 days, and a final rate of 12.86% in December 2020. Approximately 56% of Spike seropositive individuals also had immunoreactivity against the receptor binding domain (RBD) within the Spike protein, which is associated with viral neutralization. Males and females in the Cincinnati area showed nearly identical rates of past infection, and rates among Hispanics, African Americans and Caucasians were not significantly different. Interestingly, donors under 30 years of age had the highest rates of past infection, while those over 60 had the lowest. Geographic analysis showed that the West side of Cincinnati had a rate of 9.63% versus 8.13% on the East side (demarcated by Interstate-75), while the adjoining area of Kentucky was 7.04% (as demarcated by the Ohio River). These results among healthy blood donors will be critical in calculating the time needed to achieve regional herd immunity in conjunction with the national vaccination campaign.

## Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for Coronavirus disease 2019 (COVID19) was first identified in Wuhan, China in late 2019 (1,2), which thereafter spread across the globe resulting in the current pandemic. In the United States of America (USA) more than 525,000 deaths have been attributed to this virus as of March 2021, with approximately 29 million total documented cases of infection, of which over 980,000 were in the State of Ohio (3). Current efforts to curtail and possibly end the pandemic are largely dependent on the vaccine program underway across the USA and the world, with the goal of achieving herd immunity and dramatic reductions in viral spreading (4,5). Another important consideration in achieving herd immunity and the eventual end to the current pandemic is quantifying background rates of previous infection within the population (4). In general, previously infected individuals are resistant to new infection for a period, and/or they appear to have a reduced severity of disease if re-infected (6). Thus, characterizing levels of previous infection within communities across the USA will inform progression toward herd immunity with optimized vaccination strategies.

SARS-CoV-2 contains a large surface facing glycoprotein called Spike (S, ~190 kDa) that facilitates binding of the virus to the receptor angiotensin converting enzyme 2 (ACE2) on host cells, which after proteolytic cleavage of S mediates viral cellular involution and infection (7,8). The receptor-binding domain (RBD, 30 kDa) is part of the S protein that directly interacts with ACE2, and antibodies against the RBD region can mediate neutralization and protection from viral infection (7,8). The S protein is also a primary component of immunogenicity for the host response against the virus that can produce some degree of lasting immunity (7). Thus, it is not surprising that a primary strategy for vaccine development against SARS-CoV-2 involves ectopic expression of the S protein to generate host specific neutralizing antibodies, particularly those directed against the RBD region (7,8).

Rates of seropositivity for SARS-CoV-2 in voluntary blood donors in the Greater Cincinnati Metropolitan Area (GCMA) of Ohio USA were examined from August 13th - December 8th of 2020, just prior to the beginning of the nationwide vaccination program. A modified serological enzyme-linked immunosorbent assays (ELISA) assay developed by Krammer and colleagues (9,10) was implemented to examine 9,550 individuals of age range 16-91 years old for SARS-CoV-2 S protein IgG antibodies to quantify rates of prior infection in the GCMA. All positives were assayed separately for concomitant IgG sero-reactivity against the RBD portion of the S protein. A cross-section of the positive ELISA data was further examined using the Luminex immunodetection platform for potential cross-reactivity with the 4 endemic human cold-causing coronaviruses (HCoV-229E, -NL63, -OC43, and -HKU1) (11,12). Since some individuals donated blood more than once over this 5-month period, rates of decline in S protein antibody levels were documented, suggesting

some potential reduction in immunity. Finally, rates of S protein seropositivity in the GCMA due to ethnicity, gender, and geographic subregions were examined.

## Results

To document rates of previous SARS-CoV-2 infection in the GCMA leading up to the onset of the national vaccination program, blood samples from randomly presenting volunteer donors through the Hoxworth Blood Center were collected and analyzed for antibodies against the S protein by ELISA, and positives were also analyzed for RBD antibodies in a separate ELISA. Exactly 10514 samples were collected and processed from August 13th through December 8th of 2020, which represented 9550 unique donors and we determined that 802 were positive for S protein antibodies, for an overall prevalence of 8.40% (Table 1). The accuracy of this reported rate of past infection is dependent on how the laboratory ELISA was implemented and verified, which is detailed in the Methods section. The ELISA itself was based on an established protocol and set of biological reagents described by Krammer and colleagues (9,10), which was granted Emergency Use Authorization by the US Food and Drug Administration. However, a more robust protein production system based in expi-CHO cells was used to generate S and RBD proteins, which yielded greater amounts than observed using expi293 cells described by Krammer and colleagues (9,10) (Supplemental Figure 1). An improved purification protocol with quality control analytics was also instituted (Supplemental Figure 1) to ensure the purity of the preparations and that the S protein was in the trimeric configuration (Supplemental Figure 1). However, the ELISA-based reactivity of S protein antigen generated in expiCHO cells or expi293 cells was essentially identical (data not shown). The ELISA positivity cut-off was set as 3-standard deviations above background, calculated with serum samples from 2019 before the onset of the pandemic. The actual experimental value from the ELISA was 0.4039 for S protein IgG antibody and 0.4826 for RBD as optical density (OD) units, so that readings higher than these values were interpreted as positive (Table 2 and Figure 1). Importantly, this was a blinded study in which SARS-CoV-2 testing was performed post-hoc on de-identified specimens and did not modify or influence donor recruitment, eligibility or deferral for this donation or subsequent donations.

All 802 of 9550 donors with antibodies against the S protein were also evaluated for antibodies against the RBD in separate ELISAs, which showed that 446 were positive for both, a rate of 55.61% (Table 3). However, because the RBD region is ~85% smaller than the entire S protein, there are fewer total antibodies with specificity to RBD compared with S protein, explaining the reduced sensitivity of the RBD ELISA and likely why only ~56% concordance was observed (Table 3). Indeed, a sub-analysis of the 802 positive donors for S protein based on ELISA intensity

was performed, and the highest 1/3rd OD values (2.0-3.0) showed 97.3% positivity for RBD, while the lowest 1/3rd of OD values (0.4039-1.0) only showed 21.3% positivity for RBD (Table 3). Thus, those donors with the lowest levels of total S protein antibodies were less likely to have detectable RBD antibodies simply based on sensitivity issues.

The Luminex immunodetection platform was also employed to examine potential cross-reactivity with the endemic 4 human cold-causing coronaviruses that might influence S protein or RBD reactivity in the ELISAs, as well as to confirm the validity and sensitivity of the S protein ELISA (Table 4). We selected a group of 11 donor samples that were highly positive for S protein and RBD by ELISA for comparative analysis in the Luminex platform, which as expected showed a rate of 100% positivity for S, RBD and Nucleocapsid (N) protein from SARS-CoV2, but not S protein from MERS-CoV or SARS-CoV-1, which further validates the ELISA protocol (Table 4). Eleven highly characterized negative controls from the S protein ELISA were also examined and these same samples were 100% negative for S protein, RBD and N protein in the Luminex assay (Table 4). To examine the sensitivity of the S protein ELISA we also analyzed 57 donor samples that were RBD negative and relatively low in overall S protein reactivity, and in this group 67% confirmed in the Luminex assay for S protein, and 23% were positive for RBD, but only one sample was positive for N protein (Table 4). These results with the Luminex assay support the validity of the ELISA but also suggest that the ELISA is more sensitive than the Luminex platform in detecting S protein.

We also used the Luminex platform to assess correlation or cross-reactivity between donor antibody status for the S protein and positivity against the 4 human cold causing coronaviruses (HCoV-229E, -NL63, -OC43, and -HKU1). While many donors show antibodies against the 4 hCoVs in all three of our S protein ELISA groups (11 negatives, 11 high positives, and the 57 low positives), there was no correlation between antibodies against the 4-human cold-causing coronaviruses and antibody positivity or lack of positivity for SARS-CoV-2 S or RBD protein (Table 4). Thus, past infection status with the 4-human cold-causing coronaviruses did not impact S protein or RBD positivity.

Interestingly, of the 802 S protein ELISA positive donors, 108 donated blood or blood products at least 2 times from August to December 2020, and hence the study monitored maintenance or loss of antibody reactivity over time (Table 5). Analysis of these repeat donors showed 38 that had significant antibodies against S protein by ELISA on their first donation but that fell just below the assay threshold on the second donation, with an average time of 53 days (Table 5). In contrast, 24 donors maintained significant antibody reactivity and remained positive between the 2 donations, with an average time span of 69 days. However, of the 38 that lost positivity by the 2nd donation the initial composite ELISA OD value was 0.5960, while the group of 24 donors that maintained ELISA positivity between the 1st and 2nd donation had a much higher OD value of 1.47,

which compares to a total average of 1.23 OD units across all 802 S protein positive donors (Table 5). Thus, the group of 38 repeat donors that lost their antibody positive status on the 2nd donation likely reflects the low starting point of antibody reactivity in conjunction with the known gradual loss of antibodies to SARS-CoV-2 over time (13), which now was below the sensitivity of the assay.

Sample collection from August 13th - December 8th of 2020 was then split in half, which showed a significant increase in rates of positivity from the first to the second periods (Table 6). Specifically, rates of S protein ELISA positivity were 7.56% across the GCMA from August 13th through October 10th (58 days), compared with 9.24% from October 10th through December 8th, 2020 (58 days). Rates of S protein reactivity were also analyzed by month, which showed a temporal increase, culminating in a value of 12.86% in the portion of December that was evaluated (Table 6 and Figure 2). Thus, the GCMA emerged into the national vaccination phase of the pandemic with a background level of  $\geq 13\%$  of individuals likely with some degree of protection from SARS-CoV-2 re-infection.

Within the donor population dataset, we also evaluated age ranges for rates of prior infection. The 9550 donors spanned in age from 16 to 91 years, and we analyzed rates of ELISA S protein positivity based roughly on decade increments. Interestingly, the youngest group of donors from 16-30 years of age had the highest rates of antibodies against S protein compared with individuals in their 30s and 40s, while adults over 60 years of age had significantly lower rates (Table 7). This significant reduction in rates in donors over 60 may reflect greater adherence to social protective guidelines or due to reduced antibody levels in older age groups, such that they more quickly lose responsiveness in the S protein-based ELISA. Finally, gender association with rates of S protein antibodies was 8.52% in males versus 8.28% in females, which was not statistically different (Table 7).

Finally, we also analyzed geographic subregions within the GCMA for rates of S protein antibodies. Unfortunately, sampling was not large enough to examine rates based on individual zip codes, although statistical evaluation of the GCMA as larger subregions was possible, such as West versus East side, as split by Interstate 75 (I-75), and as rates in Ohio versus Kentucky, as split by the Ohio River (Table 8 and Figure 3). The data show a rate of 9.63% on the West side of Cincinnati versus 8.13% on the East side, while the Ohio portion of the GCMA was 8.79% versus 7.03% in the adjoining Kentucky region (Table 8 and Figure 3). Thus, the West side of Cincinnati had the highest rates of past SARS-CoV-2 infectivity, while the adjoining Kentucky region of the GCMA had the lowest.



## Discussion

To our knowledge the current study is the first to report rates of SARS-CoV-2 seroprevalence in the GCMA immediately preceding the national vaccination program. The total cumulative rate as of December 2020 was ~13%, which should help achieve herd immunity in the GCMA more rapidly in conjunction with the national vaccination program (14,15). With respect to immunity after viral infection, 150,000 previously infected individuals in Ohio and Florida were tracked from March 2020 -August 2020 and shown to be largely resistant to subsequent re-infection, like protection achieved with vaccination (6). In the current study here, the highest rates of past infection were observed in individuals under 30 years of age, and more generally on the West side of the GCMA compared to the East side and adjoining regions of Kentucky. Data trends failed to reveal a difference in background levels of past infectivity based on ethnicity in the GCMA as analyzed in Caucasians, African Americans, Hispanics, and Asians, although the total sampling pool of the later 3 ethnic groups was too low to achieve statistical certainty.

The detection by seroprevalence of past infection of SARS-CoV-2 is dependent on the quantitative measures of the S protein-based IgG-dependent ELISA. Thus, exact details surrounding implementation and associated quality control measures are critical in achieving accuracy of past purported infectivity rates within the population. A modified ELISA protocol from Mount Sinai Icahn School of Medicine in New York City (9,10) was implemented, which was given an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) in April of 2020 (16). Additional quality control measures included the use of 60 serum samples obtained prior to the onset of the pandemic as true negatives in generating a background value for the S protein ELISA. The entire ELISA process was also automated with robotic liquid handling and plate reading systems. Hence, the values reported here are accurate in representing the rates of past infectivity in the donor samples evaluated within the GCMA. However, it is likely that the ELISA testing platform used here will miss individuals in whom the levels of antibody have dropped below the level of detection, as previously reported (17). Thus, not all individuals infected in the early months of the pandemic will maintain a positive reading in this ELISA and as such, the composite rate calculated from the S protein ELISA likely underestimates the true rates of past infectivity in the GCMA, which is likely several percentage points higher (see below).

Individuals who present to donate blood or other blood products are not a true cross-sectional representation of a metropolitan area. Indeed, such individuals are pre-screened for communicable diseases or behaviors that are high risk for attaining such diseases. The ethnicity of the GCMA blood donor volunteers, especially during the current pandemic, is 90% or greater Caucasian and hence, under-represented in other ethnicities such as African Americans and Hispanics (18). Moreover, blood donors also tend to be healthy and have lower prevalence of

acquired chronic health conditions. However, given that this study was a post-hoc analysis of de-identified specimens, no selection bias based on donor suspicions of past infection were involved. Indeed, as discussed below, the rates of seropositivity observed here are in line with rates calculated by PCR analysis across the entire state of Ohio since the inception of the pandemic (3).

In the past year countless seroprevalence studies have been published or uploaded to preprint servers from across the USA, although very few have thus far extended to December 2020. A few of these past studies are particularly relevant and interesting to consider in relation to the current analysis. One such study examined 252,882 blood donors over 24 centers across the USA from the months of June and July 2020 (19). Vassallo et al., utilized the Ortho VITROS Anti-SARS-CoV-2 total immunoglobulin assay for the S1 region of the S protein for IgG, IgA and IgM (19), which was different from the full-length S protein ELISA detecting IgG serum levels that was produced in house and employed here. Vassallo et al., reported a rate of 1.83% in June and 2.26% in July across their entire USA sample population. Within these data were results from Chicago, which showed a rate of 2.76% in June and 3.34% in July (19). By comparison, another seroprevalence study from the Chicago area that analyzed 1545 solicited volunteers, showed a seroprevalence of 19.8% from June 24 through September 6, 2020 (20). This later study utilized the same S protein ELISA protocol from Krammer and colleagues (9,10) that we also used to investigate the GCMA, although their volunteer sample collection was based on advertising for serology evaluation (20). Hence, select community-based recruitment variables and the technical aspects of the immunodetection platform could underlie the widely disparate results discussed here. However, based on PCR measured SARS-CoV-2 molecular detection from the beginning of the pandemic until March of 2021, there were approximately 980,000 Ohioans infected with the virus. This equates to a rate of 8.23% of the state's population, which is generally consistent the data showing a rate of ~12% seropositivity as of December of 2020 in the GCMA. More interestingly, extrapolation of these data 3 additional months to the time this report was uploaded in March 2021, the rate of past infectivity in the GCMA is likely ~16%, and as stated above this approximation almost certainly slightly under-estimates the true rate due to the known gradual decline in antibody levels and the associated drop below the threshold of the S protein-based ELISA (13,17). Given all these factors and the fact that blood donors likely represent a slightly healthier cross-section of the GCMA, an overall estimated rate of past infection of roughly 20% seems reasonable for the present day in mid-March 2021.

Another study examined 177,919 seemingly random adult blood samples from across 50 States that spanned from July 27 through September 24, which reported a range of values from just under 1% to over 20%. This study used 3 different automated clinical laboratory immunodetection platforms for either S or N protein. Within their data set samples collected from August 24 -



September 24, 2020 overlap with part of our collection time, and in Ohio they report values of 2.8 to 5.0% (21). This value is also consistent with another more limited seroprevalence study with 727 samples from across the entire state of Ohio in July 2020, which incorporated mathematical modeling to predict a rate of 7% past viral infectivity (22), a value that is close to our actual data from the adjacent month of August in the GCMA.

While there are a multitude of seroprevalence studies in the literature from across the USA, only a handful appeared directly relevant to the interpretation of this study. These past studies generally support our conclusions and suggest that the ELISA implemented here was rigorous and properly calibrated, and that the donor subgroup used generated a reasonable approximation of the GCMA and likely the entire state of Ohio. The data in this study establish a rate of ~13% past SARS-CoV-2 infectivity within the GMCA by the end of 2020, and extrapolation to the present day (March of 2021) approximates a rate of 16% past infectivity, and likely even as high as 20% if depreciation in blood antibody levels over time is considered. This knowledge can impact the deployment of the vaccination program to most rapidly achieve herd immunity (15). For example, previously infected individuals might only need 1 vaccine dosage for full protection compared with a naïve individual who requires 2 vaccinations (with Moderna and Pfizer vaccines). Indeed, previously infected and recovered individuals produce a strong immunologic reaction after a single dosage of the Pfizer vaccine that is comparable to the standard 2 dose routine in naïve individuals (23); and using this information and associated strategy would augment the relative supply of the vaccine in attempting to achieve herd immunity more rapidly.

## **Methods**

### **Human Samples**

Blood samples were collected in EDTA tubes from volunteer donors presenting to the Hoxworth Blood Center according to USA FDA regulations and American Association of Blood Banks (AABB) guidelines. Specimens were de-identified and as such, the University of Cincinnati Institutional Review Board (FWA #: 000003152) ruled that these blood donor samples and their analysis as constituting non-human research for the proposed study of SARS-CoV-2 serological responsiveness. Donors are subjected to medical, social, behavioral, and travel history questionnaire to reduce risk of communicable diseases in the donated blood following USA FDA regulations and AABB guidelines. Donors who felt unhealthy including, but not limited to, elevated temperature, low blood hematocrit or signs of respiratory infection were excluded. However, donors were not questioned as to their history of SARS-CoV-2 infection, if they were symptom-free, and were not tested at the time of collection. Even though donors were de-identified, repeat donations from the same donor were obvious based on date of birth, zip code, blood group type, and gender data.

### **ELISA**

The ELISA protocol was adopted from 2 extensively annotated reports in the literature (9,10). Briefly, SARS-CoV-2 antigens for S protein and RBD were coated on 96 well plates (Corning 9018) in 1X PBS (Fisher) and stored between 1 to 7 days at 4 °C. S protein was coated at 1.0 µg/ml in 50 µl per well and the RBD protein fragment was coated at 2 µg/ml in 50 µl per well. The next day antigen plates were washed 5 times with 1X PBS + 0.1% Tween-20 (PBST) and then blotted so that the wells have no residual volume but are not technically dry. Blocking was performed with 3% non-fat dry milk (NFDM) in PBST for 1 hour at room temperature. Antigen plates were again washed 5 times with PBST. Samples received from Hoxworth Blood Center in EDTA anticoagulated tubes were heat inactivated at 56°C for 20 minutes, centrifuged and the resulting plasma was diluted 1:10 in 1X PBS and stored at -10°C until use. On day of use, samples were again diluted 1:10 in PBST + 1% NFDM. Controls on each plate consisted of a plasma sample with known high S protein antibody levels. Exactly 50 µl of the 1:100 diluted samples were added to 96-well blocked antigen plates described above (9,10). The plasma samples were allowed to incubate in the 96-well antigen plates for 2 hours at room temperature and then washed 5 times using a BioTek plate washer ELx405. Plates were blotted to remove all liquid and then 50 µl of goat anti-human IgG conjugated to horseradish peroxidase (HRP) (Jackson Labs 109-035-008) in PBST was added at a dilution of 1:10,000 for 1 hour at room temperature. Plates were washed 5 times with PBST and once with citric acid phosphate buffer, pH 5.0. The colorimetric reagent specific for HRP activity assessment,

OPD (Sigma P4664), was added in water to the plates for 15 minutes at room temperature and the reaction was stopped with the addition of 1 M H<sub>2</sub>SO<sub>4</sub>. Spectrophotometric based absorbance at 492 nm was assayed in the BioTek Synergy 2. Negative control serum samples from 60 individuals were used to establish the absolute baseline value for the S protein ELISA and 53 individuals for the RBD protein ELISA, and 3 times the standard deviation was summated to this average negative value in assigning a positive value threshold.

## Protein Production and Purification

Two different versions of the S protein were generated based on expression constructs received from Krammer and colleagues (9,10). The first construct expresses a full length trimeric and stabilized version of the S protein and the second was the much smaller RBD from within the primary sequence of the S protein. The sequence used for both proteins is based on the genomic sequence of the first virus isolate, Wuhan-Hu-1, released on January 10th, 2020, which was optimized for codon usage and mutated to remove the polybasic cleavage site, as well as addition of 2 mutations to stabilize the protein (9,10). At amino acid P1213 the sequence was also fused to a thrombin cleavage site, a T4 foldon sequence for proper trimerization and a C-terminal hexahistidine tag for purification. The sequence was cloned into a pCAGGS vector for expression in mammalian cells (9,10).

RBD and S proteins were produced by transient transfection of expiCHO™ cells (ThermoFisher, A29133) via manufacturer's instructions. Briefly, expiCHO cells were transfected with plasmid DNA (1 µg/ml of cell volume) at 6x10<sup>6</sup> cells/ml in suspension culture using the Expifectamine reagent. Transfected expiCHO cells are then cultured per the manufacturers 'max titer' protocol at 32 degrees shaking at 125 rpm for twelve days. Cell culture supernatants were harvested and filtered through a 0.2 µm membrane and both S protein and RBD were purified using a 20 mL Ni<sup>2+</sup>-charged HiPrep IMAC FF 16/10 column (Cytiva) to bind the His-tagged region engineered into each protein (9,10). The binding buffer was composed of 20 mM Tris pH 7.4, 500 mM NaCl, and 10 mM imidazole. After loading the protein onto the column, a wash was performed using 3 column volumes of binding buffer. The protein was eluted with a step gradient to 20 mM Tris pH 7.4, 500 mM NaCl, 300 mM imidazole. Fractions from the elution were buffer-exchanged into 1X PBS using a HiPrep 26/10 Desalting column (Cytiva, GE17-5087-01). For RBD, the buffer-exchanged protein was further purified using a HiLoad 26/600 Superdex 75 pg (Cytiva, GE28989334) 320 mL column with 1X PBS as the running buffer. A 10 kDa MWCO centrifugal filter unit (Amicon, ACS501024) was used to concentrate fractions containing RBD. Protein purity was validated by SDS-PAGE and western blotting using a PENTA-his antibody (Qiagen, ID:34660). Quantification of protein was performed using a BioMate 3S spectrophotometer (Thermo Scientific). The ProtParam web server was used to

calculate the molecular weight (RBD: 27,496.24 Da; Spike: 139,195.53 Da) and extinction coefficient at 280 nm (RBD: 33850 M<sup>-1</sup> cm<sup>-1</sup>; Spike: 142835 M<sup>-1</sup> cm<sup>-1</sup>) based on the amino acid sequences of RBD and S. Purified protein was stored at -20°C in 50% glycerol with 5 mM sodium azide.

## Analytical ultracentrifugation

Purified RBD and S proteins were characterized by sedimentation velocity analytical ultracentrifugation using a Beckman Coulter XL-I. RBD samples after Ni-NTA or gel filtration chromatography were dialyzed as needed into 1X PBS and spun at 48,000 rpm at 20°C in an An-60 Ti rotor. Purified spike protein from a -20°C aliquot was buffer exchanged into 1X PBS using a HiPrep 26/10 desalting column as mentioned above. The samples were then spun at 32,000 rpm at 20°C using meniscus-matching centerpieces (Spin Analytical, Inc., South Berwick, ME). Data were analyzed using SEDFIT's continuous c(s) distribution model (24), SEDANAL version 7.45 (25), or DCDT+ version 2.4.3 (26).

## Luminex

Luminex assays were performed with the One Lambda COVID Plus kit according to manufacturer's instructions (Thermo Fisher, LSCOV01). Briefly, the diluted plasma/serum samples and controls from the ELISA screen were combined in a 96-well MultiScreen filter plate (EDM Millipore, MSVN1B50), 2 µl of serum/plasma was added to 17 µl of 1X PBS and then 1 µl of 0.02 M EDTA was added for a total volume of 20 µl (final serum dilution 1:10). According to the kit the beads were prepared by vortexing and then 5 µl of this bead mix was added to each sample well. The plates were sealed and incubated for 30 min in the dark on a plate shaker at room temperature. After incubation, the seal was removed and washed with 150 µl of kit wash buffer in each well. The contents of each well were then removed with a standard vacuum manifold (EMD Millipore, #40-097) as part of the washing procedure. The plates were washed 2 more times with 150 µl of wash buffer, then 100 µl of PE-conjugated anti-human IgG (One Lambda, LS-AB2) was added at a 1:100 and incubated for 30 min. The plates were then washed 3 times with 150 µl of wash buffer per well and then 80 µl of 1X PBS was added and incubated for 5 minutes on a plate shaker. The plates were loaded into the Milliplex 200 with reporter laser 532nm / and classification laser 635nm for analysis (Luminex). Data from the instrument were prepared and analyzed using Bio-plex manager 6.1 software.

## Statistics

Means and Standard Deviations were determined for all data sets using Microsoft Excel Data Analysis Descriptive Statistics tool; histograms were made using the Microsoft Excel Data Analysis

Histogram tool and all graphs were made using Microsoft Excel. Statistics between groups were calculated using the Microsoft Excel Data Analysis t-Test: Two-Sample Assuming Unequal Variances. All z scores and the number of standard deviations from the mean of the reference population were calculated for the difference between rates of two data sets and subsequent p-value calculated using Microsoft Excel. Microsoft Excel Data Analysis Correlation tool was used to produce correlations within the Luminex data shown in Table 4.

### **Competing interest:**

None

### **Data Sharing**

Requests datasets or protocols used in this study should be directed to the corresponding author and will be made available to investigators upon reasonable request.

### **Acknowledgements**

We would like to thank Dr Florian Krammer at Mount Sinai Icahn School of Medicine for providing the mammalian expression vectors for the modified S protein and the RBD protein (9,10), upon which the ELISA platform was generated in house.

### **Sources of Funding**

This study was supported the Howard Hughes Medical Institute (to J.D.M). J.D.M was also supported by an internal grant from Cincinnati Children Research Foundation to conduct these studies on COVID-19. Contributions to this work by P.S. were financially assisted by The John Hauck Foundation, Fifth Third Bank.

### **Ethics and Reporting**

Blood samples were collected from volunteer donors presenting to the Hoxworth Blood Center following United States FDA regulations and American Association of Blood Banks (AABB) guidelines with a signed standard donor consent form. Specimens were de-identified and as such, the University of Cincinnati Institutional Review Board (FWA #: 000003152) ruled that these blood donor samples and their analysis as constituting non-human research for the proposed study of SARS-CoV-2 serological responsiveness.

## References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017.
2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. A new coronavirus associated with human respiratory disease in China. *Nature*. 2020 Mar;579(7798):265-269. doi: 10.1038/s41586-020-2008-3.
3. [https://covid.cdc.gov/covid-data-tracker/#cases\\_casesper100klast7days](https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days)
4. Clemente-Suárez VJ, Hormeño-Holgado A, Jiménez M, Benitez-Agudelo JC, Navarro-Jiménez E, Perez-Palencia N, Maestre-Serrano R, Laborde-Cárdenas CC, Tornero-Aguilera JF. Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic. *Vaccines (Basel)* 2020 Jun; 8(2): 236.
5. Batty CJ, Heise MT, Bachelder EM, Ainslie KM. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. *Adv Drug Deliv Rev*. 2021 Feb; 169: 168–189.
6. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates among Patients who Previously Tested Positive for COVID-19: a Retrospective Cohort Study. *medRxiv* 2021.02.14.21251715; doi: <https://doi.org/10.1101/2021.02.14.21251715>
7. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. *Nat Rev Immunol*. 2020 Sep 4 : 1–18. doi: 10.1038/s41577-020-00434-6
8. Dai L, Gao GF. Viral targets for vaccines against COVID-19. *Nat Rev Immunol*. 2020 Dec 18 : 1–10. doi: 10.1038/s41577-020-00480-0
9. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Arunkumar GA, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydiello T, Miorin L, Fierer DS, Lugo LA, Kojic EM, Stoeber J, Liu STH, Cunningham-Rundles C, Felgner PL, Moran T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti O, Hepojoki JM, Simon V, Krammer F. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*. 2020 Jul;26(7):1033-1036.
10. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, Tan J, Bhavsar D, Capuano C, Kirkpatrick E, Meade P, Brito RN, Teo C, McMahon M, Simon V, Krammer F. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. *Curr Protoc Microbiol*. 2020 Jun;57(1):e100.
11. Dyrda R, Hodcroft EB, Wahlund M, Neher RA, Albert J. Interactions between seasonal human coronaviruses and implications for the SARS-CoV-2 pandemic: A retrospective study in Stockholm, Sweden, 2009-2020. *J Clin Virol*. 2021 Feb 8;136:104754. doi: 10.1016/j.jcv.2021.104754.



12. Cueno ME, Imai K. Structural Comparison of the SARS CoV 2 Spike Protein Relative to Other Human-Infecting Coronaviruses. *Front Med (Lausanne)*. 2021 Jan 14;7:594439. doi: 10.3389/fmed.2020.594439.
13. Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, Hunter M, Wang H, Sahoo MK, Huang C, Yamamoto F, Manohar M, Manalac J, Otrelo-Cardoso AR, Pham TD, Rustagi A, Rogers AJ, Shah NH, Blish CA, Cochran JR, Jardetzky TS, Zehnder JL, Wang TT, Narasimhan B, Gombar S, Tibshirani R, Nadeau KC, Kim PS, Pinsky BA, Boyd SD. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. *Sci Immunol*. 2020 Dec 7;5(54):eabe0240
14. Saad-Roy CM, Levin SA, Metcalf CJE, Grenfell BT. Trajectory of individual immunity and vaccination required for SARS-CoV-2 community immunity: a conceptual investigation. *J R Soc Interface*. 2021 Feb;18(175):20200683.
15. Paul A, Kadnur HB, Ray A, Chatterjee S, Wig N. Seroprevalence and attainment of herd immunity against SARS CoV-2: A modelling study medRxiv 2021.01.22.21250328; doi: <https://doi.org/10.1101/2021.01.22.21250328>
16. Dodd RY, Xu M, Stramer SL. Change in Donor Characteristics and Antibodies to SARS-CoV-2 in Donated Blood in the US, June-August 2020. *JAMA*. 2020;324(16):1677-1679
17. Prus K, Alquist CR, Cancelas JA, Oh D. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time. *Transfusion*. 2021 Feb;61(2):651-654.
18. <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance>
19. Vassallo RR, Bravo MD, Dumont LJ, Hazegh K, Kamel H. Seroprevalence of Antibodies to SARS-CoV-2 in US Blood Donors medRxiv 2020.09.17.20195131; doi: <https://doi.org/10.1101/2020.09.17.20195131>
20. Demonbreun AR, McDade TW, Pesce L, Vaught LA, Reiser NL, Bogdanovic E, Velez ME, Hsieh RR, Klaisner C-N, Simons LM, Saber R, Ryan DT, Ison MG, Hultquist JH, Wilkins JT, D'Aquila RT, Mustanski B, McNally EM. Patterns and persistence of SARS-CoV-2 IgG antibodies in a US metropolitan site. medRxiv 2020.11.17.20233452; doi: <https://doi.org/10.1101/2020.11.17.20233452>
21. Bajema KL, Wiegand RE, Cuffe K, Patel SV, Iachan R, Lim T, Lee A, Moyse D, Havers FP, Harding L, Fry AM, Hall AJ, Martin K, Biel M, Deng Y, Meyer WA 3rd, Mathur M, Kyle T, Gundlapalli AV, Thornburg NJ, Petersen LR, Edens C. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. *JAMA Intern Med*. 2020 Nov 24:e207976. doi: 10.1001/jamainternmed.2020.7976.
22. Kline D, Li Z, Chu Y, Wakefield J, Miller WC, Turner AN, Clark SJ. Estimating Seroprevalence of SARS-CoV-2 in Ohio: A Bayesian Multilevel Poststratification Approach with Multiple Diagnostic Tests. 2020. arXiv:2011.09033
23. Manisty C, Otter AD, Treibel TA, McKnight A, Altmann DM, Brooks T, Noursadeghi M, Boyton RJ, Semper A, Moon JC. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. *The Lancet*. 2021. DOI:[https://doi.org/10.1016/S0140-6736\(21\)00501-8](https://doi.org/10.1016/S0140-6736(21)00501-8)
24. Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. *Biophys J*. 2000 Mar;78(3):1606-19.

25. Stafford WF, Braswell EH. Sedimentation velocity, multi-speed method for analyzing polydisperse solutions. *Biophys Chem.* 2004 Mar 1;108(1-3):273-9.
26. Philo JS. Improved methods for fitting sedimentation coefficient distributions derived by time-derivative techniques. *Anal Biochem.* 2006 Jul 15;354(2):238-46
27. Fleming PJ, Fleming KG. HullRad: Fast Calculations of Folded and Disordered Protein and Nucleic Acid Hydrodynamic Properties. *Biophys J.* 2018 Feb 27;114(4):856-869.

## Figure Legends

### **Figure 1. Histogram frequency of positive S protein ELISA OD values from 0.4039 to 3.000.**

The 802 Spike positive samples were grouped in bins of 0.1 OD units with the initial bin starting at 0.4039, the minimum positive Spike OD value. The maximum Spike OD of all samples was 2.998.

### **Figure 2. Percent positive S protein ELISA seroprevalence by month from August 13, 2020 to December 8, 2020.**

Month by month breakdown of the percent positive rate for 9550 unique donors. In August, 76 of 924 donors were positive (8.225%); September, 215 of 2821 donors were positive (7.621%); October, 189 of 2842 donors were positive (6.650%); November, 224 of 2201 donors were positive (10.177%); and December, 98 of 762 donors were positive (12.861%). p-value was determined from the z score for each month compared to the August positive rate for significance. Only December was significant as compared to August ( $z=-3.114$ ,  $p=0.0018$  Two-tailed) while September, October and November were not significantly different from each other. The number of samples collected per month is shown in each bar.

### **Figure 3. Seroprevalence of protein antibodies in the Greater Cincinnati Metropolitan Area.**

Map image courtesy of Google Maps (<https://www.google.com/maps>). Greater Cincinnati Metropolitan Area (GCMA) as defined by the United States Census Bureau ([https://data.census.gov/cedsci/map?q=All%20counties%20in%20Ohio&q=310M500US17140&tid=A\\_CSDP5Y2019.DP02&layer=VT\\_2019\\_310\\_M5\\_PY\\_D1&cid=DP02\\_0093PE&palette=Teal&break=5&classification=Natural%20Breaks&mode=customize](https://data.census.gov/cedsci/map?q=All%20counties%20in%20Ohio&q=310M500US17140&tid=A_CSDP5Y2019.DP02&layer=VT_2019_310_M5_PY_D1&cid=DP02_0093PE&palette=Teal&break=5&classification=Natural%20Breaks&mode=customize)) and reported in the 2010 AGE, RACIAL, GENDER AND MARITAL STRUCTURE OF GREATER CINCINNATI. The Cincinnati Metropolitan Statistical Area (MSA) includes: Butler, Brown, Clermont, Hamilton, and Warren Counties in Ohio; Boone, Bracken, Campbell, Gallatin, Grant, Kenton, and Pendleton Counties in Kentucky; and Dearborn, Franklin, and Ohio Counties in Indiana. The indicated data show percent of seropositivity for Spike antibodies shown by the indicated regions.

**Table 1. Donor S protein IgG antibody positivity rate in Hoxworth blood samples collected from August 13, 2020 to December 8, 2020.**

Samples	# of positive	% positive
9550	802	8.40

Total number of unique donors assayed in the GCMA between August to December 2020. The number of positive donors was determined by S protein antibody reactivity in the in-house ELISA assay described here.

**Table 2. Mean S and RBD raw ELISA OD values from human serum prior to 2020.**

	Mean of negative controls	Standard deviation	Mean + 3 standard deviations
Spike OD	0.1284	0.09185	0.4039
RBD OD	0.1482	0.1115	0.4826

The final ELISA raw data for antibody reactivity against S or RBD proteins, as measured in OD values at 492 nm in an automated spectrophotometric plate reader. The assay standard deviation was determined with 60 and 53 negative control serum samples taken before the COVID19 pandemic in 2019 for S and RBD, respectively. Three standard deviation units was added to the negative control value in setting the assay threshold positivity value shown for S and RBD.

**Table 3. S and RBD positivity rates analyzed over 3 ranges of S protein antibody OD values.**

	# of Spike Pos	# of RBD Pos	% RBD and Spike positive
All positives:	802	446	55.61
Spike OD range			
0.4039 to 1.000	409	87	21.27
1.001 to 2.000	205	176	85.85
2.000 to 3.000	188	183	97.34

Exactly 802 donors that were positive for S protein antibodies were also assessed for RBD ELISA based antibody positivity, and while only 55.61% were positive for both S and RBD, this rate depended on the strength of the S protein antibody levels over the 3 different OD ranges shown. Thus, those donors with high S protein antibodies were much more like to be positive for RBD antibodies.

**Table 4. Comparison of S protein ELISA versus Luminex immunodetection of S protein, RBD, N and status of the 4 hCoVs and MERS and SARS-CoV-1**

	<b>ELISA</b>		<b>Luminex</b>								
Negative controls (sample numbers)	Spike protein OD	RBD protein OD	SARS-CoV-2 Spike	SARS-CoV-2 Spike RBD	SARS-CoV-2 Nucleocapsid Protein	HCoV-229E Spike S1	HCoV-HKU1 Spike S1	HCoV-NL63 Spike S1	HCoV-OC43 Spike S1	MERS-CoV Spike S1	SARS-CoV Spike S1
N1	0.132	0.312	16.5	25.5	28.5	752.3	427.5	681.5	1451.5	18.5	25.5
N2	0.159	0.196	39	4.5	2	1480.8	78.5	352.5	287.5	1.5	17.5
N3	0.138	0.136	19	10.5	11	3016.3	539.5	538	1343.5	5.5	16.5
N4	0.127	0.11	49	26.5	1091.5	844.3	1322.5	90	170.5	7.5	22.5
N5	0.056	0.018	30.5	3.5	30.5	726.3	525.5	462.5	543.5	1.5	6.5
N6	0.251	0.21	29	57	73.5	3204.8	257.5	433.5	581	43.5	45
N7	0.178	0.178	17	41	45.5	1494.8	253.5	777.5	213	31.5	33.5
N8	0.203	0.181	113	38	17.5	613.3	835.5	287.5	545.5	10	13.5
N9	0.128	0.12	74.5	12.5	15	1419.8	696	412	293.5	3.5	12.5
N10	0.152	0.207	61	25.5	19.5	2794.8	456.5	938.5	506	7.5	14.5
N11	0.089	0.185	14	14.5	8.5	1496.8	548.5	463.5	596.5	3.5	10.5
	<b>ELISA</b>		<b>Luminex</b>								
Positive Spike and Positive RBD Samples	Spike protein OD	RBD protein OD	SARS-CoV-2 Spike	SARS-CoV-2 Spike RBD	SARS-CoV-2 Nucleo-capsid Protein	HCoV-229E Spike S1	HCoV-HKU1 Spike S1	HCoV-NL63 Spike S1	HCoV-OC43 Spike S1	MERS-CoV Spike S1	SARS-CoV Spike S1
B1	2.904	2.991	21290.3	8917.7	5821.3	260.5	320.3	768.3	81.7	21.7	128.3
B3	2.111	2.701	14502.8	4787.2	4541.3	3033	1447.3	403.3	1511.2	7.7	138.3
B4	2.637	3.020	24563.3	11541	7229.3	3173	1588.3	477.3	583.2	11.7	100.3
B5	3.000	2.944	16272.3	6672.2	4689.3	2183	1399.3	593.8	360.2	7.7	44.8
B6	2.218	3.125	25727.3	13068	6875.8	2881.5	287.3	1614.3	755.7	8.7	61.3
B7	1.380	3.049	24344	8703	7509	3266	970	1208	1324.5	11	106
B8	1.432	3.132	25231.3	10711	6537.3	856	821.3	626.3	1900.2	23.7	103.3
B9	2.019	2.952	16536.8	6820.7	5045.3	4267.5	460.8	2000.3	1277.7	10.2	153.3
B10	2.643	3.042	27812.8	17379	9306.3	1560	1060.3	1241.3	406.2	9.7	403.3
B11	2.701	2.662	23273.8	9145.7	14334.3	3689	332.3	1295.8	598.7	21.7	259.3

Sample number <1.0 for Spike, RBD neg	ELISA		Luminex								
	Spike protein OD	RBD protein OD	SARS- CoV-2 Spike	SARS- CoV-2 Spike RBD	SARS-CoV-2 Nucleocapsid Protein	HCoV- 229E Spike S1	HCoV- HKU1 Spike S1	HCoV- NL63 Spike S1	HCoV- OC43 Spike S1	MERS- CoV Spike S1	SARS- CoV1 Spike S1
C1	0.506	0.159	35	47	78	1431	3386	593	2136	4	99
C2	0.508	0.097	352	13	40	5246	1581	342	2480	3	13
C3	0.51	0.133	47	41	203	438	3263	183	3974	4	84
C4	0.51	0.258	300	13	24	505	405	82	838	2	15
C5	0.513	0.169	431	15	48	1801	1455	677	4787	2	20
C6	0.516	0.134	243	11	12	2062	797	138	1793	2	13
C7	0.553	0.104	430	32	470	947	443	356	1160	13	28
C8	0.561	0.065	1297	16	21	776	1873	741	2410	4	20
C9	0.563	0.146	578	20	34	5654	3184	1058	5784	6	22
C10	0.566	0.234	450	13	30	3929	597	289	1405	8	11
C11	0.571	0.043	343	18	32	4008	1637	698	4811	3	19
C12	0.574	0.222	1086	11	24	1004	1753	816	2718	4	16
C13	0.579	0.298	44	25	60	1126	796	568	1911	2	14
C14	0.581	0.191	580	7	41	659	1517	351	2412	2	64
C15	0.587	0.255	213	11	18	3960	3817	667	3054	2	3
C16	0.597	0.313	59	20	42	1292	1934	319	1182	5	21
C17	0.601	0.309	2517	423	363	267	1089	73	2073	4	88
c20	0.602	0.284	36	83	95	1954	3003	258	4087	6	57
C21	0.613	0.319	25	24	51	3276	2953	206	547	3	18
C22	0.614	0.173	413	35	49	3405	2164	551	2615	4	44
C23	0.615	0.225	17	6	22	3331	206	406	1701	3	12
C24	0.621	0.173	2352	1552	5752	218	1205	66	3895	8	124
C25	0.629	0.342	25	12	27	1690	2301	640	149	4	22
C26	0.636	0.08	276	132	249	750	636	304	639	1	179
C27	0.639	0.337	582	190	502	4874	3450	240	3941	5	389
C28	0.641	0.055	29	7	22	824	313	296	157	3	11
C29	0.642	0.15	223	24	68	2828	2071	376	1308	2	16
C30	0.645	0.22	156	102	240	3734	1090	245	2153	11	129
C31	0.671	0.299	7	11	27	932	352	332	351	3	26
C32	0.675	0.149	144	44	62	2791	650	384	506	5	51
C33	0.684	0.399	100	20	32	392	306	206	645	3	20

C34	0.695	0.332	851	13	31	2196	615	848	210	6	14
C35	0.696	0.246	10	10	12	871	201	290	485	2	3
C36	0.701	0.373	27	14	60	2098	833	244	2285	2	16
C37	0.706	0.133	53	71	37	1322	489	302	1443	3	49
C38	0.713	0.094	1796	9	18	5052	347	879	1168	4	14
C39	0.72	0.304	1676	10	12	1118	1872	36	3155	3	11
C40	0.726	0.348	389	41	33	1842	4402	598	2966	5	43
C41	0.727	0.309	70	13	9	1223	548	241	3071	2	10
C42	0.749	0.377	891	480	585	1891	1783	91	2138	6	344
C43	0.765	0.19	2001	12	24	1519	259	473	3312	2	11
C44	0.771	0.13	13	11	85	2403	1090	598	1536	3	16
C45	0.781	0.131	1096	26	466	3722	1554	1781	1731	10	21
C46	0.785	0.084	790	152	287	4108	5443	171	3325	4	258
C47	0.791	0.205	330	11	18	3357	1197	183	1453	1	15
C48	0.809	0.082	1546	648	33	1676	622	439	754	5	9
C49	0.809	0.141	1478	80	166	3797	2331	960	1709	11	124
C50	0.813	0.189	2329	180	459	307	1825	384	1959	3	335
C51	0.815	0.372	140	39	104	1083	219	550	217	3	49
C52	0.861	0.32	233	30	119	425	741	125	2896	9	30
C53	0.883	0.122	19	45	41	214	204	187	623	2	48
C54	0.898	0.161	701	10	19	2354	275	100	2070	5	20
C55	0.961	0.321	979	75	144	2244	3249	1127	2419	2	65
C56	0.976	0.194	2897	41	84	4761	2614	798	807	42	63
C57	0.996	0.097	3252	837	353	816	731	244	1570	4	20

Samples consisted of 11 negative controls from the S protein ELISA, 11 that were high positive for both S and RBD protein in the ELISA, and 57 samples with a progressive increase in S protein OD value (2nd column) from the ELISA, but that were RBD negative. The Luminex threshold for positivity was set from the negative controls as the average plus 3 standard deviations for SARS-CoV-2 S protein = 134.05, RBD protein of = 73.63, and Nucleocapsid protein = 1088.50. Two columns showing data from the S protein and RBD protein ELISA are given for comparison to all the Luminex immunodetection data for S protein, RBD, Nucleocapsid, HCoV-229E S1, HCoV-HKU1 S1, HCoV-NL63 S1, HCoV-OC43 S1, MERS-CoV S1 and SARS-CoV-1 S1. The green boxes are values that were considered positive in the Luminex assay.



**Table 5. Assessment of S raw values in donors that donated blood at least 2 times, some maintained positivity for spike protein antibodies, while some lost positivity.**

	N	Mean Pos OD	Mean # of days	p value
Pos-Neg	38	0.596	52.8	
Stayed Pos	24	1.466	69.3	0.0119*
All Positives	802	1.228		

p-value is for comparison of mean OD value of Pos-Neg donors compared with mean OD value of "Stayed-Pos" donors. The Pos-Neg donors were positive for S protein antibodies on first read only for the average number of days in between the 2 donations as shown. The "Stayed-Pos" donors had at least 2 positive S protein antibody readings over the time shown in days. The donors that lost positivity had a low first OD reading, while the donors that maintained positivity on their 2nd readings began with a higher initial S protein ELISA OD value.

**Table 6. Rates of GCMA S protein antibody positivity broken into 2 successive time periods from August to December 2020.**

	Number of Spike OD positive	N	% positive	
All	802	9550	8.398	
				p value
1st 58 days	362	4786	7.564	
2nd 58 days	440	4764	9.236	0.0016

The first 58 days spanned from August to October 2020, while the second 58-day period spanned from the rest of October to the first part of December 2020.

**Table 7. Rates of S protein antibody positivity by ELISA from the indicated donor age ranges or by gender.**

		Number of donors	Number of Spike OD positive	Percent positive	p value
Age group of donors	16-30	1442	136	9.431	0.0286
	31-40	1447	108	7.464	n.s.
	41-50	1571	140	8.912	n.s.
	51-60	2185	200	9.153	n.s.
	60+	2905	218	6.984	0.0144
Sex of donors	Male	4564	389	8.523	
	Female	4986	413	8.283	n.s.


Only the 16-30 age range and the 60+ age range was statistically different from 31-40 age range, but the 31-40, 41-50 and 51-60 were not statistically different from each other. Rates in males and females were not significantly different.

**Table 8. Rate of positive S antibody positivity clustered by regions within the GCMA that was tied to home address zip codes.**


Ohio*	Number of donors	Number of positive donors	Percent positive	p value
West of I-75	3136	302	9.630	
East of I-75	4266	347	8.134	0.0123
Ohio	7418	652	8.789	
Kentucky	2132	150	7.036	0.005

\*Excludes Kentucky and 17 people (3 positive) in zip codes divided evenly by I-75. However, Ohio was also summated along with the additional 17 donors on the I-75 border to compare against Kentucky zip codes on the south side of the Ohio River, but within the GCMA.

**Figure 1.**



**Figure 2:**



**Figure 3.**

